Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
AIM Vaccine Co., Ltd. Class H ( (HK:6660) ) has issued an announcement.
AIM Vaccine Co., Ltd. reported its annual results for the year ended December 31, 2024, showing a revenue increase of 8.2% to RMB 1,285,031,000 and a gross profit rise of 5.8% to RMB 953,508,000. The company significantly reduced its loss attributable to owners by 78.7% compared to the previous year, indicating an improvement in financial performance, despite ongoing challenges in selling, distribution, and administrative expenses.
More about AIM Vaccine Co., Ltd. Class H
AIM Vaccine Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating in the biotechnology industry with a focus on vaccine development and production.
YTD Price Performance: -26.38%
Average Trading Volume: 6,040,603
Technical Sentiment Signal: Buy
For detailed information about 6660 stock, go to TipRanks’ Stock Analysis page.